Head & Neck Pathology: Pleomorphic Adenoma (PA)
High-Yield Revision Notes for Board Review & PG Entrance Examinations
Pleomorphic Adenoma (PA), also known as a “Benign Mixed Tumor,” is the most common neoplasm of the salivary glands. It accounts for approximately 60–70% of all parotid tumors. The term “pleomorphic” refers to its highly variable histological appearance, displaying a mixture of epithelial and mesenchymal-like elements.
1. Epidemiology & Clinical Presentation
- Location: The Parotid Gland is the most common site (specifically the superficial lobe). In minor salivary glands, it is most commonly found on the palate.
- Demographics: Peak incidence in the 4th to 6th decades of life; slightly higher female predilection.
- Clinical Presentation: Presents as a slow-growing, painless, firm, solitary, mobile mass.
- Red Flag: Sudden rapid growth, fixation, or the development of facial nerve palsy suggests malignant transformation (Carcinoma Ex-Pleomorphic Adenoma).
2. Histopathological Features
The hallmark of PA is the presence of epithelial cells intermingled with mesenchymal-like tissue (myxoid, chondroid, or hyalinized stroma).
- Epithelial component: Duct-like structures, strands, and sheets of luminal cells and myoepithelial cells.
- Mesenchymal component: Myxoid, chondroid (cartilage-like), or mucoid background.
- Crucial Feature: The tumor possesses a false capsule or incomplete encapsulation. This is clinically significant because the tumor often exhibits “pseudopodia” or microscopic extrusions beyond the main mass.
3. Management & Surgical Pearl
- Diagnostic Workup: Fine Needle Aspiration Cytology (FNAC) is the gold standard for preoperative diagnosis.
- Surgical Principle: Enucleation is absolutely contraindicated due to the risk of tumor rupture and high rate of local recurrence.
- Standard Procedure: Superficial Parotidectomy (for superficial lobe tumors) or Total Conservative Parotidectomy, with preservation of the facial nerve. The surgery must include a margin of normal salivary gland tissue to account for the incomplete capsule.
4. Key Board Examination Facts
| Point | High-Yield Detail |
|---|---|
| Molecular Marker | Associated with PLAG1 (Pleomorphic Adenoma Gene 1) rearrangements at 8q12. |
| Recurrence | High recurrence rate if enucleated; usually presents as multicentric (multiple nodules) upon recurrence. |
| Malignant Transformation | Carcinoma Ex-Pleomorphic Adenoma (CXPA) occurs in long-standing untreated cases; risk increases with time (10% over 20 years). |
| Most Common Site | Parotid gland (specifically the tail of the parotid). |